Novozymes A/S
Denmark · DK0060336014 · reports in EUR · Europe
The answers
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Is it growing?Fair
- Revenue +8.5% in the year to Dec 31, 2025, on the year before.
- Is it a good business?Fair
- It earned 5.4% on its shareholders' equity in the year to Dec 31, 2025.
- Is it safe?Good
- Equity is 66% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in EUR.
€4.2B
revenue
20%
operating margin
€584M
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2024 | Dec 2025 | |
|---|---|---|
| Revenue | €3.8B | €4.2B |
| Operating profit | €501M | €817M |
| Net profit to shareholders | €306M | €584M |
| Earnings per share | €0.67 | €1.25 |
| Cash from operations | €1.0B | €1.2B |
| Capital spending | €338M | €410M |
| Cash | €280M | €275M |
| Total assets | €15.2B | €16.3B |
| Equity | €11.2B | €10.9B |
What they do
In the company's own words, from the annual report.
Novonesis is a pure biology player, with deep scientific special-ization in microbiology and industrial fermentation.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.